Cargando…

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

Trastuzumab is effective in about half of HER2-positive breast cancer patients. The PI3K/Akt signalling pathway plays an important role in the process of primary and secondary resistance to anti-HER2 targeted therapy. We evaluated the relationship between expression, activation and subcellular local...

Descripción completa

Detalles Bibliográficos
Autores principales:	GRELL, PETER, FABIAN, PAVEL, KHOYLOU, MARTA, RADOVA, LENKA, SLABY, ONDREJ, HRSTKA, ROMAN, VYZULA, ROSTISLAV, HAJDUCH, MARIAN, SVOBODA, MAREK
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2012
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583615/ https://www.ncbi.nlm.nih.gov/pubmed/22842582 http://dx.doi.org/10.3892/ijo.2012.1576

Ejemplares similares

MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients
por: Svoboda, Marek, et al.
Publicado: (2012)

miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib
por: Merhautova, Jana, et al.
Publicado: (2015)

Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma
por: Redova, Martina, et al.
Publicado: (2012)

Identification and functional screening of microRNAs highly deregulated in colorectal cancer
por: Faltejskova, Petra, et al.
Publicado: (2012)

MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications
por: Sana, Jiri, et al.
Publicado: (2011)

MicroRNAs in colorectal cancer: translation of molecular biology into clinical application
por: Slaby, Ondrej, et al.
Publicado: (2009)

Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the Central European population
por: Hezova, Renata, et al.
Publicado: (2012)

Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer
por: Slaby, Ondrej, et al.
Publicado: (2012)

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab
por: Mlcochova, Jitka, et al.
Publicado: (2015)

MiR-34b is associated with clinical outcome in triple-negative breast cancer patients
por: Svoboda, Marek, et al.
Publicado: (2012)

Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy
por: Slaby, Ondrej, et al.
Publicado: (2010)

Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy
por: Slaby, Ondrej, et al.
Publicado: (2010)

Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma
por: Mlcochova, Hana, et al.
Publicado: (2016)

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
por: Nemecek, Radim, et al.
Publicado: (2016)

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9
por: Vychytilova-Faltejskova, Petra, et al.
Publicado: (2017)

Identification of microRNA signatures in umbilical cord blood associated with maternal characteristics
por: Juracek, Jaroslav, et al.
Publicado: (2019)

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
por: Hrstka, Roman, et al.
Publicado: (2013)

Genome‐wide identification of urinary cell‐free microRNAs for non‐invasive detection of bladder cancer
por: Juracek, Jaroslav, et al.
Publicado: (2018)

FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer
por: Grell, Peter, et al.
Publicado: (2023)

Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus
por: Hezova, Renata, et al.
Publicado: (2015)

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
por: Kiss, I., et al.
Publicado: (2017)

Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy
por: Holanek, Milos, et al.
Publicado: (2022)

Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors
por: Kopkova, Alena, et al.
Publicado: (2019)

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
por: Lakomy, Radek, et al.
Publicado: (2017)

Evaluation of laparoscopic resection of colorectal carcinoma from the viewpoint of molecular biology
por: Skrovina, Matej, et al.
Publicado: (2011)

Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer
por: Koleckova, Marketa, et al.
Publicado: (2021)

PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study
por: Obermannova, Radka, et al.
Publicado: (2022)

Novel classes of non-coding RNAs and cancer
por: Sana, Jiri, et al.
Publicado: (2012)

Non-invasive prognostic protein biomarker signatures associated with colorectal cancer
por: Surinova, Silvia, et al.
Publicado: (2015)

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma
por: Besse, Lenka, et al.
Publicado: (2015)

Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival
por: Sana, Jiri, et al.
Publicado: (2018)

Cancer Cell Response to Anthracyclines Effects: Mysteries of the Hidden Proteins Associated with These Drugs
por: Tyleckova, Jirina, et al.
Publicado: (2012)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein
por: Valianatos, Georgios, et al.
Publicado: (2017)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway
por: Yang, Yun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s5bl4f6e68vhe964qnqj765bbp